Provide feedbackProvide feedback
Home :: Pediatrics

Vertex's Kalydeco approved for CF

Tuesday, January 31 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration approved Vertex Pharmaceuticals Inc.'s Kalydeco (ivacaftor), the first drug developed to treat the underlying cause of cystic fibrosis (CF). Kalydeco is indicated for patients aged 6 years or older who have CF and at least one copy of the G551D mutation in the CF transmembrane conductance regulator (CFTR) gene. The therapy, which was designated as an orphan drug, was approved under the FDA's priority review program ahead of the targeted Prescription...

The Food and Drug Administration approved Vertex Pharmaceuticals Inc.'s Kalydeco (ivacaftor), the first drug developed to treat the underlying cause of cystic fibrosis (CF).

Kalydeco is indicated for patients aged 6 years or older who have CF and at least one copy of the G551D mutation in the CF transmembrane conductance regulator (CFTR) gene.

The therapy, which was designated as an orphan drug, was approved under the FDA's priority review program ahead of the targeted Prescription Drug User Fee Act goal date of April 18.

The approval was supported by findings from two Phase III trials--STRIVE and ENVISION--in which patients with CF who had at least one copy of the G551D mutation were treated with Kalydeco or placebo. Data showed that the Kalydeco-treated patients experienced significant and sustained improvements in lung function and other disease measures, including weight gain and certain quality-of-life measurements, when compared with the patients who received placebo.

The patients who received Kalydeco also experienced significantly fewer pulmonary exacerbations, which are periods of worsening in the signs and symptoms of CF that often require treatment with antibiotics and hospital visits. Moreover, fewer individuals in the Kalydeco treatment groups than in the placebo groups discontinued treatment because of adverse events.

The company is seeking approval to market the drug in Europe.

Latest News

UCB's Keppra approved as adjunctive therapy for partial-onset seizures in infants, young children Verusmed

Wednesday, January 25 2012 | Comments
Evidence Grade 0 What's This?
UCB Inc.'s Keppra (levetiracetam) tablets and oral solution were approved by the Food and Drug Administration for the treatment of partial-onset seizures in infants and children aged 1 month or older with epilepsy, effectively expanding the drug's use for partial-onset seizures to include a younger patient population, according to the firm's parent company, Tags: Epilepsy


New formulations of Gilead's Viread approved for use in children with HIV Verusmed

Thursday, January 19 2012 | Comments
Evidence Grade 0 What's This?
The Food and Drug Administration approved Gilead Sciences Inc.'s Viread (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for the treatment of HIV-1 in children aged 2 to 12 years.

Gilead received approval of its supplemental New Drug Application for three lower-strength, once-daily tablets of Viread in doses of 150 mg, 200 mg and 250 mg for children aged 6 to 12...


Actavis launches first generic version of Novartis' Ritalin LA Verusmed

Wednesday, January 04 2012 | Comments
Evidence Grade 0 What's This?
Actavis Group launched its methylphenidate hydrochloride extended-release capsules, which are the first generic equivalents of Novartis AG's Ritalin LA.

The Food and Drug Administration approved Actavis' generic version of the drug, which is indicated for the treatment of attention-deficit/hyperactivity disorder, last month; it is...
Tags: ADHD, ADHD


Biogen Idec, Isis collaborate to develop treatment for spinal muscular atrophy Verusmed

Wednesday, January 04 2012 | Comments
Evidence Grade 0 What's This?
Biogen Idec Inc. and Isis Pharmaceuticals Inc. entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize Isis' ISIS-SMNRx, an investigational antisense drug, for the treatment of spinal muscular atrophy (SMA).

Under the terms of the agreement,...



Pediatrics Conference Coverage
Videos